Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apremilast Efficacy Results Disappoint But May Be Enough For Commercial Success

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene’s PDE-4 inhibitor met the primary endpoint in the first of two pivotal Phase III trials, but analysts worried that the treatment effect was less than that seen in a Phase II study. Some analysts still see a strong niche position for apremilast in treatment-naïve patients before they move on to biologic therapy.

You may also be interested in...

Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline

The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.

Celgene Has A Swift Start For Pomalyst Launch

The biotech did better than Wall Street expected with its first sales figures for multiple myeloma drug Pomalyst. But it’s still very early going. Continuing to expand its hematology oncology franchise, including main revenue-driver Revlimid, remains a primary focus for Celgene.

Celgene Lays Out Catalysts For Strong 2013, Highlights Apremilast

Celgene reported strong sales for key products, led by Revlimid, during its year-end 2012 call. The biopharma affirmed 2013 guidance, detailing the key regulatory and commercial drivers that will power the global expansion of its hematology, oncology, and immunology franchises. In particular, it highlighted the commercial potential for apremilast.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts